Study of drug or biologic devices on human subjects is called Clinical research . Regulation is responsible for each drug approval and the escape from the ethical issues related to studies in human subjects. . It keeps a check on parallelism between government regulations and clinical trials during the drug approval process. The regulatory department works in accordance to the regulatory agencies like FDA, EMEA,MHRA, and TGA etc .

Pharma Regulatory affairs Department is a multiple functionary body which manages multiple tasks such as:

Pharmaceutical administration & Management
Regulatory Strategies
Auditing and compliance
GMP Certification
Quality assurance
Pharmacovigilance and ADR Reporting

The guidelines for regulation are provided by the Food and Drug Administration(FDA).These are in the form of Good Manufacturing Practices(GMP), Good Clinical Practices(GCP),International Conference of Harmonization (ICH) etc.

Regulatory Strategies are designed to make every move productive. The mode of work ensures that no mistakes are repeated that are liable to cause delay in the approval process and are responsible for GMP Certification provided provided as per WHO norms and ensures quality. Certification is provided by CDSCO (Central Drug Standard Control Organization)state licensing authorities for various drug related practices like import, testing and drug manufacture.

Each drug has to undergo the FDA approval process before it is officially launched for marketing. The primary requirement of approval is the compliance with regulatory guidelines.

The compliance inspection is done to verify the corrective actions after the regulatory action has been taken. The firm under inspection has to provide all of its corrective action plan after a violation inspection.
For Cause Inspections are done when a problem is brought under consideration of the agency.
Full Inspection is done if there is minimum knowledge of firm's GMPs.
The abbreviated inspection is done if GMPs of the firm have a good record and no previous recalls have been made.

Regulatory Strategy:

When non-compliant conditions are identified during the inspection,A voluntary compliance is developed on case-by-case basis before recommending a regulatory action to correct the found violation. In domestic firms, all the corrections are managed by district offices. The approaches range from recalls of the products, development of new procedures, modifications, testings to shut down operations.

Failure of any one system leads to issue of warrants an out of control consideration to all the firm's operations. And if one profile fails,it leads to the failure of all its dependent operations.

If the management is unable to provide the corrective actions, regulatory actions are taken. The nature of action depends on the deviation from GMPs. Actions are taken in accordance to the regulatory procedures manual.

In a situation where there is no serious risk to human health,and a voluntary correction is needed, an untitled letter can be issued and .the firm should mention its corrective plans to achieve the voluntary compliance. While if the risk is very high profile, seizure should be considered. In case of repetitive violators, and if there is no likelihood of correction,prosecution may also be considered.